perpetuity. It is made available under a CC-BY 4.0 International license .

## 1 Prevalence of chlamydia, gonorrhoea, and trichomoniasis among male and female

# 2 general populations in sub-Saharan Africa from 2000-2024: A systematic review and

## 3 meta-regression analysis

4

5 Julia Michalow<sup>1\*</sup>, Lauren Hall<sup>1</sup>, Jane Rowley PhD<sup>2</sup>, Rebecca L. Anderson<sup>1</sup>, Quinton Hayre<sup>3</sup>, R.

- 6 Matthew Chico PhD<sup>4</sup>, Olanrewaju Edun<sup>1</sup>, Jesse Knight PhD<sup>1</sup>, Salome Kuchukhidze PhD<sup>3</sup>, Evidence
- 7 Majaya<sup>5</sup>, Domonique M. Reed PhD<sup>3</sup>, Oliver Stevens<sup>1</sup>, Magdalene K Walters<sup>1</sup>, Remco PH Peters
- 8 PhD<sup>2</sup>, Anne Cori PhD<sup>1</sup>, Prof Marie-Claude Boily PhD<sup>1</sup>, Jeffrey W. Imai-Eaton PhD<sup>1,3</sup>
- 9 <sup>1</sup> MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College
- 10 London, London, United Kingdom
- 11 <sup>2</sup> Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World
- 12 Health Organization, Geneva, Switzerland
- 13 <sup>3</sup> Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
- 14 Chan School of Public Health, Boston, Massachusetts, USA
- 15 <sup>4</sup> Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of
- 16 Hygiene & Tropical Medicine, London, United Kingdom
- 17 <sup>5</sup> Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family
- 18 Medicine, University of Cape Town, Cape Town, South Africa
- 19
- 20 \* Corresponding author: Julia Michalow (j.michalow21@imperial.ac.uk)

#### 21 Abstract

22 Background: Sub-Saharan Africa (SSA) has the highest sexually transmitted infection (STI) prevalence globally, but information about trends and geographic variation is limited by sparse 23 24 aetiologic studies, particularly among men. This systematic review assessed chlamydia, 25 gonorrhoea, and trichomoniasis prevalence by sex, sub-region, and year, and estimated male-to-26 female prevalence ratios for SSA.

27 Methods: We searched Embase, MEDLINE, Global Health, PubMed, and African Index Medicus 28 for studies measuring STI prevalence among general populations from January 1, 2000, to 29 September 17, 2024. We adjusted observations for diagnostic test performance and used log-30 binomial mixed-effects meta-regressions to estimate prevalence trends and sex-prevalence 31 ratios.

32 Findings: Of 5202 records identified, we included 211 studies from 28 countries. In 2020, 33 estimated prevalence among 15-49-year-olds in SSA for chlamydia was 6.6% (95%CI: 5.0-8.2%, 34 n=169 observations) among females and 4.7% (3.4-6.1%, n=33) among males, gonorrhoea was 35 2.4% (1.4-3.3%, n=171) and 1.7% (0.7-2.6%, n=31), and trichomoniasis was 6.8% (3.6-9.9%, n=188) and 1.7% (0.7-2.7%, n=19). Male-to-female ratio estimates were 0.61 (0.53-0.71) for 36 37 chlamydia, 0.81 (0.61-1.09) for gonorrhoea, and 0.23 (0.18-0.28) for trichomoniasis. From 2010-38 2020, chlamydia prevalence increased by 34.5% (11.1-62.9%) in SSA, while gonorrhoea and 39 trichomoniasis trends were not statistically significant. Chlamydia and gonorrhoea prevalence 40 were highest in Southern and Eastern Africa, whereas trichomoniasis was similar across sub-41 regions.

- 42 Interpretation: SSA has a high, geographically varied STI burden, with increasing prevalence of
- 43 chlamydia. Region-specific sex-prevalence ratios differed from existing global ratios and should
- 44 be considered in future burden estimates. Enhanced sex-stratified surveillance is crucial to guide
- 45 national programmes and reduce STI prevalence in SSA.
- 46 Funding: Gates Foundation, Imperial College London, NIH, UKRI

#### 47 Background

48 The World Health Organization (WHO) has established targets to reduce the incidence of sexually 49 transmitted infections (STIs) by 2030.<sup>1</sup> Achieving these targets requires ambitious scale-up of 50 national STI prevention and control programmes, particularly in sub-Saharan Africa (SSA) where 51 STI prevalence is highest globally.<sup>1</sup> However, monitoring and optimising these programmes is 52 challenging due to high rates of asymptomatic infection, variable health-seeking behaviour, 53 limited diagnostic capacity necessitating syndromic management, and weak surveillance 54 systems.<sup>2</sup> STI prevalence estimates are crucial for evaluating progress toward WHO targets but 55 are hindered by infrequent population-representative studies, especially among men.<sup>3</sup>

56 Estimates of curable STI prevalence in SSA are limited. WHO publishes global and regional 57 prevalence and incidence estimates for curable STIs, including chlamydia (Chlamydia trachomatis, CT), gonorrhoea (Neisseria gonorrhoeae, NG), and trichomoniasis (Trichomonas 58 59 *vaginalis*, TV), approximately every four years.<sup>4–9</sup> These focus on global geographic regions and do 60 not report sub-regional variation or temporal trends. The Global Burden of Disease (GBD) study generates global, regional, and national prevalence and incidence trends for several STIs.<sup>10</sup> Both 61 62 estimation approaches depend heavily on available data and underlying model assumptions. 63 Due to limited data among men, WHO and GBD have derived male-to-female prevalence ratios from global data and applied these in most regions to support male prevalence estimates.<sup>5,8,10</sup> 64 65 Although WHO reviews its global ratios prior to each estimation round, values have not been 66 updated since 1999 for trichomoniasis and 2005 for chlamydia and gonorrhoea.<sup>5,8</sup> Additionally, 67 several systematic reviews have assessed the prevalence of curable STIs in SSA sub-regions 68 among pregnant women,<sup>11,12</sup> women participating in HIV prevention trials,<sup>13</sup> or women living with 69 HIV,<sup>14</sup> but their generalisability beyond the specified populations is limited and these reviews 70 have not examined changes in STI prevalence over time.

71 We therefore conducted a systematic review of studies on chlamydia, gonorrhoea, and 72 trichomoniasis prevalence among adults considered representative of the general population 73 (i.e. not conducted among groups identified as key populations, as defined in WHO guidelines on 74 HIV, STIs, and viral hepatitis<sup>1</sup>) in SSA from 2000 to 2024. We performed meta-analyses to assess 75 variations in STI prevalence by sex, sub-region, and over time. To inform future regional and global 76 STI burden estimation efforts, we derived updated male-to-female prevalence ratios specific to 77 SSA.

#### 78 **Methods**

#### 79 Search strategy

80 We systematically searched Embase (Ovid), MEDLINE (Ovid), Global Health (Ovid), PubMed, and 81 African Index Medicus from 1 January 2000 to 17 September 2024 for studies assessing the 82 prevalence of chlamydia, gonorrhoea, and trichomoniasis in SSA. Search term domains included 83 relevant terms and synonyms for "sexually transmitted infections" and "sub-Saharan Africa" (Table S1). We also searched citations from relevant published systematic reviews.<sup>7-9,11-20</sup> 84

85 Eligibility criteria and study selection

perpetuity. It is made available under a CC-BY 4.0 International license .

86 We included studies reporting sex-stratified empirical data on the prevalence of chlamydia, 87 gonorrhoea, or trichomoniasis among adults from the general population in SSA between 2000 88 and 2024. We considered studies to represent the general population if they enrolled participants 89 from antenatal care (ANC), family planning, or gynaecology clinics; primary healthcare or other 90 outpatient services; educational institutions; or community venues (e.g., social spaces or places 91 of worship); or recruited participants for HIV or STI prevention trials (baseline data only) or

- 92 population-representative surveys. We excluded studies if participants sought treatment for STI 93 symptoms or infertility or were enrolled exclusively from populations living with HIV or key
- 94 populations.
- 95 We included studies with participants aged 12 years or older who were tested using 96 internationally recognised aetiologic diagnostic tests with urogenital specimens (urine, urethral, 97 or cervicovaginal samples), and excluded studies that only collected pharyngeal or rectal 98 samples. We also excluded case reports, commentaries, longitudinal and randomised controlled 99 studies reporting only post-baseline outcomes, and studies with fewer than 15 participants. We
- 100 used the UN M49 standard to define SSA and its sub-regions (Table S2).<sup>21</sup>
- 101 Search results were managed and de-duplicated using Covidence systematic review software
- 102 (Veritas Health Innovation, Melbourne, Australia).<sup>22</sup> Researchers (DMR, EM, JM, JWI-E, JK, LH,
- 103 MKW, OE, OS, OH, RLA, SK) independently double-screened title and abstract records for
- 104 eligibility and assessed full text articles for inclusion. A third reviewer resolved discrepancies.
- 105 Data extraction
- 106 Researchers (JM, LH, RLA, QH) independently double-extracted prevalence observations 107 (number of individuals with a positive result of the total number tested) for each study with 108 stratification by country, sex, and population group, as available. We also recorded information 109 on study characteristics, participant characteristics, and diagnostic methodology (Table S3).
- 110 Discrepancies were resolved through consensus.
- 111 If outcomes from the same study were reported in multiple articles, we preferentially extracted
- 112 observations from the largest sample or, if samples were the same size, the first published article.
- 113 For studies collecting samples from multiple anatomical sites, we extracted only urogenital
- 114 results. If multiple diagnostic tests were conducted, we extracted outcomes from the test and
- 115 sample type with highest sensitivity and specificity for pathogen identification (Table S4). We
- 116 preferentially extracted non-stratified rather than HIV-stratified outcomes, if both were reported.
- 117 Data analysis
- 118 We adjusted study prevalence estimates to account for imperfect diagnostic test sensitivity and
- specificity, using a previously described Bayesian approach.<sup>23</sup> Sensitivity and specificity values 119
- for each test category were collated from published literature, with preference for characteristics 120
- 121 published by the WHO (Table S4).<sup>5,23,24</sup>
- 122 For studies that did not report data collection dates (n=26), we imputed the midpoint year of data
- 123 collection by subtracting the median publication lag from the publication year (three years, based
- 124 on the difference between the data collection midpoint year and year of publication among
- 125 studies with dates reported). For one study spanning multiple sub-regions without country- or

perpetuity. It is made available under a CC-BY 4.0 International license .

126 region-specific data reported,<sup>25</sup> we classified the study sub-region according to where most 127 participants had been recruited.

128 To estimate sub-regional trends in sex-specific STI prevalence in SSA, we fit log-binomial mixed-129 effects meta-regressions for each pathogen. Fixed effects included year (midpoint of data 130 collection), study population (ANC attendees, family planning clinic attendees, gynaecology 131 clinic attendees, primary healthcare or other outpatient facility attendees, students, community 132 members recruited from non-clinical venues, HIV/STI prevention trial participants, and 133 population-representative survey participants), sex (female, male), age group (younger adults 12-134 25 years, all adults ≥ 12 years), HIV status (HIV negative, non-stratified HIV status), diagnostic test 135 (nucleic acid amplification test [NAAT], culture, direct fluorescent antibody, enzyme 136 immunosorbent assay, rapid antigen test, wet mount), sub-region (Western and Central Africa 137 [WCA], Eastern Africa [EA], or Southern Africa [SA]), year and sub-region interaction term, and sex 138 and sub-region interaction term. A year and sex interaction term was not included due to limited 139 observations of male prevalence. We combined Western and Central Africa due to limited 140 prevalence observations in Central Africa. Study-level random intercepts allowed for between-141 study heterogeneity. Fitted models were used to predict the prevalence of each infection among 142 male and female adults by sub-region between 2000 and 2024, using reference categories for 143 covariates in the model (study population: ANC attendees, HIV status: non-stratified, diagnostic 144 test: NAAT). We report estimates for sub-regions and all of SSA for 2020. SSA estimates were 145 obtained by weighting sub-regional predictions with sex-matched population size for adults aged 15-49 years in 2020, according to UN World Population Prospects 2024.<sup>26</sup> Standard errors were 146 147 determined using the delta method.<sup>27</sup>

148 To assess sex differences in prevalence, we estimated male-to-female prevalence ratios using 149 observations from all studies (between-study ratios) and for the subset of studies providing 150 estimates for both sexes (within-study ratios). We estimated between-study ratios using 151 previously described meta-regression models. We determined within-study ratios using the 152 same meta-regression approach, but without fixed effects for population group and an 153 interaction term for sex and sub-region, due to limited observations. We also derived pooled 154 within-study ratios without adjusting for any covariates.

155 We assessed sensitivity of prevalence estimates, trends, and male-to-female prevalence-ratios 156 to adjustments for diagnostic performance by comparing results from models using all available 157 observations versus only NAAT-diagnosed observations, with and without accounting for test 158 sensitivity and specificity. Unless indicated otherwise, all main results reflect observations 159 adjusted for diagnostic test performance. Results are presented as means with 95% confidence 160 intervals (95% CIs). Model coefficients are presented as adjusted prevalence ratios (aPRs), with 161 confidence intervals calculated on the log scale prior to exponentiation. Analyses were 162 conducted in R version 4.2.3; Bayesian diagnostic test performance adjustments used rstan version 2.26.21<sup>28</sup> and meta-regression modelling used glmmTMB version 1.1.8.<sup>29</sup> 163

We pre-registered our study with PROSPERO (CRD: 42023420384)<sup>30</sup> and reported according to 164 the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.<sup>31</sup> 165 166 The Imperial College Research Ethics Committee approved analysis of secondary data for this

- 167 study (ICREC #6365329).

#### 168 Results

#### 169 Search results and scope

170 We identified 11,136 records through the database search, of which 5,934 were duplicates and 171 5,202 were screened (Figure 1). Of these, 783 full-text articles were assessed and 301 met 172 eligibility criteria. After adding 11 articles identified through citation searching and excluding 98 173 articles with duplicate study observations, we included 214 articles from 211 unique studies, 174 from which we extracted 614 prevalence observations (NG=203, CT=203, TV=208; Table S5). Most 175 studies were in Eastern Africa (N=90/211, 42.7%), followed by Western and Central (N=71/211, 176 33.6%), and Southern (N=59/211, 28.0%) Africa (Table 1). Studies were conducted in 28 different 177 sub-Saharan African countries, with most in South Africa (N=53/211, 25.1%), Nigeria (N=38/211, 178 18.0%), Kenya (N=26/211, 12.3%), Tanzania (N=20/211, 9.5%), and Uganda (N=19/211, 9.0%) 179 (Figure S1). Study populations were predominantly ANC attendees (N=85/211, 40.3%), primary 180 healthcare or outpatient department attendees (N=30/211, 14.2%), and HIV/STI prevention trial 181 participants (N=24/211, 11.4%). Few studies were among population-representative survey 182 samples (N=11/211, 5.2%). Most studies were solely among females (N=174/211, 82.5%). A 183 limited number included both sexes (N=29/211, 13.7%) or males only (N=8/211, 3.8%). Studies 184 were predominantly among all adults (N=180/211, 85.3%), rather than restricted to younger 185 adults (N=31/211, 14.6%). Across all studies, most enrolled within the 15-49-year age range 186 (N=109/211, 51.7%), while others included younger and/or older participants (N=45/211, 21.3%), 187 reported only a minimum adult age (N=37/211, 17.5%), or did not report age ranges (N=20/211, 188 9.5%).

#### 189 Sexually transmitted infection prevalence

190 In 2020, estimated prevalence of chlamydia in SSA was 6.6% (95%CI: 5.0-8.2%, number of observations (n)=169) among females and 4.7% (3.4-6.1%, n=33) among males, gonorrhoea was 191 192 2.4% (1.4-3.3%, n=171) and 1.7% (0.7-2.6%, n=31), and trichomoniasis was 6.8% (3.6-9.9%, 193 n=188) and 1.7% (0.7-2.7%, n=19), respectively (Figure 2A). From 2010 to 2020, chlamydia 194 prevalence increased by 34.5% (11.1-62.9%) in SSA, while trends for gonorrhoea (3.3% increase 195 [-20.2-33.9%]) and trichomoniasis (17.8% increase [-3.8-34.9%]) were not statistically significant 196 (Table 2, Figure 2B).

197 Sub-regional variations in prevalence were similar for chlamydia and gonorrhoea (Table 2, Figure 198 2A). Among females, relative to Southern Africa, the prevalence of chlamydia and gonorrhoea 199 were lowest in Western and Central Africa (aPR<sub>CT</sub>: 0.31 [0.22-0.43], aPR<sub>NG</sub>: 0.36 [0.23-0.57]), 200 followed by Eastern Africa (aPR<sub>ct</sub>: 0.38 [0.35-0.41], aPR<sub>NG</sub>: 0.64 [0.56-0.74]). Similarly for males, 201 prevalence was lower in Western and Central ( $aPR_{CT}$ : 0.38 [0.32-0.46],  $aPR_{NG}$ : 0.58 [0.44-0.78]) 202 and Eastern Africa (aPR<sub>CT</sub>: 0.32 [0.19-0.53], aPR<sub>NG</sub>: 0.50 [0.23-1.10]) compared to Southern Africa. 203 For trichomoniasis, female prevalence was similar across sub-regions (WCA aPR<sub>TV</sub>: 0.94 [0.68-204 1.31], EA aPR<sub>TV</sub>: 1.01 [0.85-1.21]), while male prevalence was higher in Eastern (aPR<sub>TV</sub>: 2.45 [1.66-205 3.61]) than Southern Africa.

206 Time trends for each infection varied across sub-regions. Chlamydia prevalence increased in 207 Eastern (aPR<sub>cT</sub> per year: 1.07 [1.05-1.09]) and Southern Africa (aPR<sub>cT</sub>: 1.02 [1.00-1.04]), while 208 trichomoniasis prevalence decreased in Southern Africa (aPR<sub>TV</sub>: 0.96 [0.92-0.99]) only. 209 Gonorrhoea prevalence was stable across all three sub-regions (Table 2, Figure 2B).

perpetuity. It is made available under a CC-BY 4.0 International license .

210 Across study populations, there was no evidence that the prevalence of any infection differed

- 211 compared to ANC attendees, except for lower trichomoniasis prevalence among family planning
- 212 clinic attendees (aPR: 0.54 [0.32-0.90]). Studies diagnosing chlamydia with a rapid antigen test 213
- (aPR<sub>ct</sub>: 2.94 [1.76-4.92]), gonorrhoea with culture (aPR<sub>NG</sub>: 1.60 [1.00-2.54]), and trichomoniasis 214 with wet mount (aPR<sub>TV</sub>: 1.61 [1.14-2.29]) had higher prevalence than those that used NAAT, after
- 215 accounting for diagnostic test performance (Table 2).

### 216 Male-to-female prevalence ratio estimates

217 In SSA, male-to-female prevalence ratio estimates for each infection were similar when 218 estimated using adjusted between-study ratios (all available data), adjusted within-study ratios 219 (paired data), or unadjusted pooled within-study ratios (Figure 3, Table 2, Table S6). Male-to-220 female prevalence ratio estimates (adjusted between-study) for SSA in 2020 were 0.61 (0.53-221 0.71) for chlamydia, 0.81 (0.61-1.09) for gonorrhoea, and 0.23 (0.18-0.28) for trichomoniasis 222 (Figure 3, Table 2). Between-study prevalence ratios were consistent across sub-regions for 223 chlamydia (WCA:0.63 [0.43-0.93], EA:0.61 [0.53-0.70], SA:0.61 [0.55-0.66]), but varied for 224 gonorrhoea (WCA:1.05 [0.54-2.04], EA:0.69 [0.56-0.85], SA:0.76 [0.65-0.90]) and trichomoniasis 225 (WCA:0.14 [0.09-0.20], EA:0.36 [0.30-0.44], SA:0.15 [0.11-0.20]; Table 2).

### 226 Sensitivity analyses of diagnostic test performance

227 Prevalence estimates in 2020 were consistent for all three infections when derived using all 228 available or NAAT-only observations, with or without accounting for diagnostic test performance 229 (Table 2, Table S7-S9, Figure S2). Temporal trends for chlamydia and gonorrhoea also remained 230 consistent across sub-regions. However, for trichomoniasis, all-observation models showed a 231 prevalence decline in Southern Africa (aPR: 0.96 [0.92-0.99] with and without test performance), 232 while NAAT-only models did not (with test performance: 0.96 [0.90-1.02]; without: 0.96 [0.92-233 1.01]; Table 2, Table S7-S9, Figure S3). Between-study and within-study male-to-female 234 prevalence ratios were consistent for all three infections, whether derived using all available or 235 NAAT-only observations. However, accounting for test performance led to higher ratios for 236 gonorrhoea and lower ratios for chlamydia and trichomoniasis (Table 2, Table S7-S9, Figure S4).

### 237 Discussion

238 Our analysis estimated the prevalence of chlamydia, gonorrhoea and trichomoniasis among 239 general populations in SSA between 2000 and 2024. We estimated a higher burden of curable 240 STIs among females (6.9% chlamydia, 1.8% gonorrhoea, and 7.6% trichomoniasis in 2020) than 241 males (4.2%, 1.5%, and 1.7% respectively), which exceeded global prevalence estimates (3.2%, 242 0.7%, and 2.7% for both sexes in 2020, respectively).<sup>9</sup> Geographic variation was substantial; 243 prevalence of chlamydia and gonorrhoea was highest in Southern Africa, followed by Eastern 244 Africa and then Western and Central Africa. Trichomoniasis prevalence was similar across sub-245 regions for females but was highest in Eastern Africa for males. The prevalence of chlamydia 246 increased considerably in Eastern and Southern Africa over the study period, while gonorrhoea 247 was stable, and trichomoniasis decreased in Southern Africa.

248 Our central estimates of STI prevalence in 2020 differed from those reported by WHO for the African region and GBD for SSA.<sup>9,10</sup> For females, our estimates were higher for chlamydia (6.9% 249 250 vs. WHO:5.5%, GBD:4.5%), similar for gonorrhoea (1.8% vs. WHO:1.6%, GBD:1.7%), and lower

perpetuity. It is made available under a CC-BY 4.0 International license .

251 for trichomoniasis (7.6% vs. WHO:12.0%, GBD:12.6%). For males, our estimates were higher for 252 chlamydia (4.2% vs. WHO:4.0%, GBD:2.5%), gonorrhoea (1.5% vs. WHO:1.2%, GBD:1.2%), and trichomoniasis (1.7% vs. WHO:1.3%, GBD:1.5%).<sup>9,10</sup> These differences reflect our broader study 253 inclusion criteria, incorporation of more recent studies, and analysis of temporal trends to reflect 254 255 sub-regional changes in prevalence. Compared to existing global male-to-female prevalence 256 ratios, our SSA ratio estimates were lower for chlamydia (WHO: 0.80 and GBD: 0.91), and 257 intermediate for gonorrhoea (WHO: 0.86 and GBD: 0.71) and trichomoniasis (WHO: 0.10 and GBD: 0.25; Figure 3).<sup>5,8,10</sup> Although our analysis indicated sub-regional ratio variation, data 258 259 limitations precluded more detailed exploration. Given these differences, future estimation 260 exercises should prioritise using region-specific ratios to capture local epidemiologic 261 differences, although sparse male prevalence data can hinder ratio estimation.

262 The spatial distribution of chlamydia and gonorrhoea prevalence mirror that of HIV prevalence in 263 SSA, characterised by highest burden in Southern Africa, followed by Eastern Africa, and lowest in Western and Central Africa.<sup>32</sup> This is likely due to shared behavioural risk factors and biological 264 synergies that facilitate co-infection.<sup>33</sup> Despite evidence suggesting that trichomoniasis 265 increases HIV transmission and acquisition risk,<sup>34</sup> prevalence variations were not observed 266 267 across sub-regions. This could reflect limitations in study availability and diagnostics, missing 268 covariates, or incomplete adjustment for covariates such as age.<sup>35</sup> Greater integration of STI and 269 HIV services remains important for their effective mitigation in high-burden areas.<sup>1</sup>

270 The increasing prevalence of chlamydia in Eastern and Southern Africa and decreasing 271 prevalence of trichomoniasis in Southern Africa have not been documented previously. Previous 272 STI burden assessments reported stable prevalence over time for chlamydia and gonorrhoea in 273 Kenya and South Africa<sup>36,37</sup> or did not estimate time trends for curable STIs in SSA.<sup>8,11–14</sup> For 274 chlamydia, increases in prevalence are particularly concerning given the severe, long-term health 275 consequences of untreated infection, including chronic pelvic pain, infertility, ectopic pregnancy, 276 and other adverse pregnancy outcomes, along with an increased risk of HIV transmission.<sup>1</sup> For 277 trichomoniasis, declines in prevalence warrant cautious interpretation. Our trend estimates were 278 sensitive to the diagnostic tests included, due to more widespread use of NAAT rather than wet 279 mount microscopy in recent studies.

280 Our analysis was primarily limited by sparse and heterogenous data. Our systematic search 281 identified only 211 studies in 28 of 48 SSA countries. There were particularly few studies in Central 282 Africa (12 studies in 6 countries) and among men (37 studies in 15 countries). We were therefore 283 unable to generate estimates specific to Central Africa or to determine whether temporal 284 prevalence trends differed by sex. Our estimates for Southern Africa relied predominantly on 285 studies conducted in South Africa (51 of 59 studies in the sub-region), which limited our ability to 286 assess the representativeness of both these studies and our estimates for the broader sub-287 region.

288 Limitations related to study representativeness and reporting, and adjustments made in our 289 analysis, may have influenced our estimates. Given the lack of population-representative 290 studies, we used ANC attendees as the reference category for our prevalence estimates. At least 291 65% of studies focused exclusively on sexually active individuals, including antenatal, family 292 planning, and gynaecology clinic attendees, and HIV/STI prevention trial participants. We

perpetuity. It is made available under a CC-BY 4.0 International license .

293 considered these groups to be representative of the general population, which may result in 294 overestimating STI prevalence compared to the total adult population. Variability in reporting 295 across studies hindered our adjustment of estimates for HIV prevalence, granular age groups, or 296 urban/rural location, which likely influenced sub-regional heterogeneities. Furthermore, our 297 adjustments for diagnostic test performance may have overestimated prevalence, particularly for 298 trichomoniasis, due to the poor sensitivity of widely used wet mount microscopy. Our reliance on 299 previously published WHO performance data, without accounting for improvements in 300 diagnostic accuracy over time, may have resulted in over-adjusting recent study observations and 301 thus overestimating temporal trends.

302 Despite these limitations, our systematic review provides a comprehensive analysis of 303 chlamydia, gonorrhoea, and trichomoniasis prevalence in SSA. We have addressed gaps in 304 previous prevalence estimates by examining temporal trends and sub-regional variation, while 305 incorporating studies from a range of populations considered representative of the general 306 population. Our multiple analytical approaches yielded similar male-to-female prevalence ratio 307 estimates, and our extensive sensitivity analyses of diagnostic test performance adjustments 308 have strengthened the robustness of our findings.

- 309 In conclusion, we estimated a high and geographically varied prevalence of three curable STIs in
- 310 SSA, with concerning increases in chlamydia prevalence over time. Male-to-female prevalence
- 311 ratios for SSA and its sub-regions differed from existing WHO and GBD global ratios, emphasising
- 312 the need to account for epidemiologic variations in future STI burden estimates and control
- 313 strategies. Strengthening sex-stratified aetiologic surveillance, through both regular sentinel
- 314 surveys and population-representative prevalence studies, is essential for progressing toward
- 315 WHO targets and reducing the STI burden in SSA.

### 316 Contributors

317 JM, JR, JWI-E, and M-CB conceptualised the study. DMR, EM, JM, JWI-E, JK, LH, MKW, OE, OS, QH,

318 RLA, and SK screened abstracts and full text articles for inclusion. JM, LH, RLA, and QH extracted

- 319 data from included studies. JM assessed diagnostic test validity, collated diagnostic test 320 performance characteristics, and performed the data analysis. JM wrote the initial manuscript
- 321 draft, which was revised with input from all authors. All authors approved the final manuscript.

### 322 **Declaration of interests**

323 The authors have no competing interests to declare.

### 324 Funding

325 JM acknowledges funding from the Imperial College President's PhD Fund. EM and JWI-E 326 acknowledge funding from the Gates Foundation (INV-005576). AC, JK, JM, JWI-E, M-CB, MKW, 327 OE, OS, and RLA acknowledge funding from the MRC Centre for Global Infectious Disease 328 Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) 329 and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO 330 Concordat agreement and is also part of the EDCTP2 programme supported by the European 331 Union. SK was supported by the National Institute of Child Health and Human Development of 332 the National Institutes of Health under award number R01HD101351. MKW was supported by the

National Institute of Allergy and Infectious Diseases of the National Institutes of Health underaward number R01AI152721.

335 Under the grant conditions of UKRI and the Gates Foundation, a Creative Commons Attribution

336 4.0 Generic License (CC BY) has already been assigned to any Author Accepted Manuscript

- version arising from this submission. The content is solely the responsibility of the authors and
- does not necessarily represent the official views of the funders.

## 339 Data sharing

Data extracted from included studies and used for analysis are available as supplementary
 material. Code and data reproducing the analysis is available from
 <u>https://github.com/juliamichalow/sti-prevalence-ratios</u>.

#### 344 References

345 346	1	World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva, 2022.			
347 348	2	World Health Organization. Framework for monitoring sexually transmitted infections and strengthening surveillance. Geneva, 2024.			
349 350	3	World Health Organization. Report on global sexually transmitted infection surveillance. Geneva, 2018.			
351 352	4	Word Health Organization. Global prevalence and incidence of selected curable sexuall transmitted infections. Overview and estimates. Geneva, 2001.			
353 354 355	5	World Health Organization. Prevalence and incidence of selected sexually transmitted infections: Methods and results used by WHO to generate 2005 estimates. Geneva, 2011.			
356 357	6	World Health Organization. Global incidence and prevalence of selected curable sexu transmitted infections - 2008. Geneva, 2012 DOI:10.1016/s0968-8080(12)40660-7.			
358 359 360	7	Newman L, Rowley J, Hoorn S Vander, <i>et al</i> . Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. <i>PLoS One</i> 2015; <b>10</b> : 1–17.			
361 362 363	8	Rowley J, Hoorn S Vander, Korenromp E, <i>et al</i> . Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. <i>Bull World Health Organ</i> 2019; <b>97</b> : 548–62.			
364 365	9	World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections. Web Annex 2: Data methods. Geneva, 2021.			
366 367 368 369 370	10	Ferrari AJ, Santomauro DF, Aali A, <i>et al.</i> Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. <i>The Lancet</i> 2024; <b>403</b> : 2133–61.			
371 372 373	11	Nyemba DC, Haddison EC, Wang C, Johnson LF, Myer L, Davey DJ. Prevalence of cura STIs and bacterial vaginosis during pregnancy in sub-Saharan Africa: a systematic reand meta-analysis. <i>Sex Transm Infect</i> 2022; <b>98</b> : 484–91.			
374 375 376	12	Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub Saharan Africa: a systematic review. <i>JAMA</i> 2012; <b>307</b> : 2079–86.			
377 378 379	13	Torrone EA, Morrison CS, Chen PL, <i>et al</i> . Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. <i>PLoS Med</i> 2018; <b>15</b> : e1002511.			

Jarolimova J, Platt LR, Curtis MR, *et al.* Curable sexually transmitted infections among
women with HIV in sub-Saharan Africa. *Aids* 2022; **36**: 697–709.

- Kassa ZY, Hussen S, Hadra N, Moges Y, Bonja F. Prevalence of Neisseria gonorrhoeae
   infection among women of reproductive age in sub-Saharan Africa: a systematic review
   and meta-analysis. *The European Journal of Contraception & Reproductive Health Care* 2020; 25: 365–71.
- Hussen S, Wachamo D, Yohannes Z, Tadesse E. Prevalence of chlamydia trachomatis
   infection among reproductive age women in sub Saharan Africa: a systematic review and
   meta-analysis. *BMC Infect Dis* 2018; **18**. https://pubmed.ncbi.nlm.nih.gov/30477441/
   (accessed Sept 4, 2024).
- 390 17 Vaezzadeh K, Sepidarkish M, Mollalo A, *et al.* Global prevalence of Neisseria
  391 gonorrhoeae infection in pregnant women: a systematic review and meta-analysis. *Clin*392 *Microbiol Infect* 2023; **29**: 22–31.
- Joseph Davey DL, Shull HI, Billings JD, Wang D, Adachi K, Klausner JD. Prevalence of
  Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income
  Countries From 2010 to 2015: A Systematic Review. Sex Transm Dis 2016; 43: 450–8.
- Whelan J, Abbing-Karahagopian V, Serino L, Unemo M. Gonorrhoea: a systematic review
   of prevalence reporting globally. *BMC Infectious Diseases 2021 21:1* 2021; **21**: 1–23.
- Williams R, Auzenbergs M, Etombi CL, *et al.* P187. Curable STIs among pregnant women
  attending antenatal care facilities in low- and middle-income countries from 2000 to
  2022: A systematic review and meta-analysis. In: 23rd IUSTI World Congress. 2022.
- 401 21 UN Statistics Division. Standard country or area codes for statistical use (M49).
  402 https://unstats.un.org/unsd/methodology/m49/ (accessed June 14, 2023).
- 403 22 Covidence systematic review software. Veritas Health Innovation, Melbourne, Australia.
  404 https://www.covidence.org/ (accessed Dec 2, 2024).
- 405 23 Michalow J, Walters MK, Olanrewaju E, *et al.* Aetiology of vaginal discharge, urethral
  406 discharge, and genital ulcer in sub-Saharan Africa: A systematic review and meta407 regression. *PLoS Med* 2024; **21**: e1004385.
- 408 24 World Health Organization. Laboratory and point-of-care diagnostic testing for sexually
  409 transmitted infections, including HIV. Geneva, 2023.
- Delany-Moretlwe S, Hughes JP, Bock P, *et al.* Cabotegravir for the prevention of HIV-1 in
  women: results from HPTN 084, a phase 3, randomised clinical trial. *The Lancet* 2022; **399**: 1779–89.
- 41326UN Population Division. Data Portal. https://population.un.org/dataportal/home414(accessed Aug 21, 2023).
- 415 27 Hogg R V, McJean JW, Craig AT. Introduction to mathematical statistics, Eighth ed.
  416 Boston: Pearson, 2019.

417 418	28	Stan Development Team. RStan: the R interface to Stan. R package version 2.21.2. 2020. https://mc-stan.org/ (accessed May 29, 2023).		
419 420	29	Generalized linear mixed models using Template Model Builder. R package version 1.1. 2023; published online April 5.		
421 422 423	30	Hall L, Michalow J, Imai-Eaton JW, Boily M-C, Rowley J, Chico M. Sexually transmitted infection prevalence ratios in sub-Saharan Africa: a systematic review and meta-analysis. <i>PROSPERO</i> 2024.		
424 425	31	Page MJ, McKenzie JE, Bossuyt PM, <i>et al</i> . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ</i> 2021; <b>372</b> .		
426 427	32	Joint United Nations Programme on HIV/AIDS. IN DANGER: UNAIDS Global AIDS Update. Geneva, 2022.		
428 429 430	33	Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. <i>J Int AIDS Soc</i> 2019; <b>22</b> . DOI:10.1002/jia2.25355.		
431 432	34	Kissinger P, Adamski A. Trichomoniasis and HIV interactions: A review. <i>Sex Transm Infect</i> 2013; <b>89</b> : 426–33.		
433 434	35	Workowski KA, Bachmann LH, Chan PA, <i>et al</i> . Sexually Transmitted Infections Treatment Guidelines, 2021. <i>MMWR Recommendations and Reports</i> 2021; <b>70</b> : 1.		
435 436 437	36	Kularatne RS, Niit R, Rowley J, <i>et al</i> . Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: Estimates using the Spectrum-STI model, 1990-2017. <i>PLoS One</i> 2018; <b>13</b> : 205863.		
438 439 440 441	37	Korenromp EL, Mahiané G, Rowley J, <i>et al</i> . Estimating prevalence trends in adult gonorrhoea and syphilis in low- and middle-income countries with the Spectrum-STI model: Results for Zimbabwe and Morocco from 1995 to 2016. <i>Sex Transm Infect</i> 2017; <b>93</b> : 599–606.		
442 443				

#### 444 Table 1: Summary of characteristics for included studies.

	Group	Chlamydia	Gonorrhoea	Trichomoniasis	Total
Variable		(N=139)	(N=140)	(N=162)	(N=211)
Sub-region <sup>1</sup>	Western Africa	20 (14.4%)	20 (14.3%)	51 (31.5%)	59 (28.0%)
	Central Africa <sup>2</sup>	10 (7.2%)	8 (5.7%)	8 (4.9%)	12 (5.7%)
	Eastern Africa	69 (49.6%)	70 (50.0%)	63 (38.9%)	90 (42.7%)
	Southern Africa	49 (35.3%)	51 (36.4%)	46 (28.4%)	59 (28.0%)
	Multiple sub-regions <sup>3</sup>	1 (0.7%)	1 (0.7%)	1 (0.6%)	1 (0.5%)
Study	2000-2004	27 (19.4%)	32 (22.9%)	34 (21.0%)	45 (21.3%)
midpoint	2005-2009	18 (12.9%)	19 (13.6%)	21 (13.0%)	27 (12.8%)
year <sup>1,4</sup>	2010-2014	35 (25.2%)	31 (22.1%)	38 (23.5%)	51 (24.2%)
	2015-2019	42 (30.2%)	41 (29.3%)	54 (33.3%)	64 (30.3%)
	2020-2024	18 (12.9%)	17 (12.1%)	15 (9.3%)	25 (11.8%)
Population	ANC attendees	39 (28.1%)	42 (30.0%)	75 (46.3%)	85 (40.3%)
group <sup>1</sup>	FP attendees	12 (8.6%)	12 (8.6%)	11 (6.8%)	17 (8.1%)
	GYN attendees	6 (4.3%)	8 (5.7%)	11 (6.8%)	14 (6.6%)
	PHC/OPD attendees	22 (15.8%)	22 (15.7%)	20 (12.3%)	30 (14.2%)
	Students	15 (10.8%)	11 (7.9%)	15 (9.3%)	19 (9.0%)
	Community members⁵	15 (10.8%)	16 (11.4%)	6 (3.7%)	17 (8.1%)
	HIV/STI prevention trial	22 (15.8%)	22 (15.7%)	22 (13.6%)	24 (11.4%)
	participants <sup>6</sup>				
	Population-representative	10 (7.2%)	10 (7.1%)	8 (4.9%)	11 (5.2%)
	survey participants				
Sex	Female only	106 (76.3%)	109 (77.9%)	143 (88.3%)	174 (82.5%)
	Male only	7 (5.0%)	5 (3.6%)	7 (4.3%)	8 (3.8%)
	Both sexes (stratified)	26 (18.7%)	26 (18.6%)	12 (7.4%)	29 (13.7%)
Age group	Adult (12+ years)	112 (80.6%)	116 (82.9%)	140 (86.4%)	180 (85.3%)
	Youth (12–25 years)	27 (19.4%)	25 (17.9%)	22 (13.6%)	31 (14.7%)
HIV status <sup>1,7</sup>	HIV-negative	37 (26.6%)	38 (27.1%)	38 (23.5%)	46 (21.8%)
	Non-stratified	103 (74.1%)	103 (73.6%)	125 (77.2%)	166 (78.7%)

445 N: number of studies, ANC: antenatal care, FP: family planning, GYN: gynaecology clinic, PHC/OPD: Primary 446 healthcare or outpatient department.

447 <sup>1</sup>The same study is included in more than one subcategory if it reports across different variable levels or when multiple 448 levels are relevant.<sup>2</sup> Western and Central Africa combined for analysis. <sup>3</sup>Study without country- or region-specific 449 reporting was allocated to Eastern Africa for analysis, according to where most participants were recruited. <sup>4</sup>Midpoint 450 year between start and end of data collection period. 5Community members recruited through non-clinical venues, 451 such as social spaces or places of worship. 6Studies reporting baseline data among trial participants. 7Studies exclusively among populations living with HIV were excluded. Data were preferentially extracted and analysed without

452 453 stratifying by HIV status if both were reported.

455 Table 2: Adjusted prevalence ratios for chlamydia, gonorrhoea, and trichomoniasis in sub-Saharan Africa, 456 estimated via log-binomial generalised linear mixed-effects models

	Chlamydia	Gonorrhoea	Trichomoniasis
Variable	aPR (95% CI)	aPR (95% CI)	aPR (95% CI)
Intercept	0.14 (0.11-0.18)	0.03 (0.02-0.05)	0.09 (0.07-0.12)
Sub-region			
Western and Central	0.31 (0.22-0.43)	0.36 (0.23-0.57)	0.94 (0.68-1.31)
Eastern	0.38 (0.35-0.41)	0.64 (0.56-0.74)	1.01 (0.85-1.21)
Southern	Ref	Ref	Ref
Sub-region:Sex <sup>1</sup>			
Western and Central:Male	0.63 (0.43-0.93)	1.05 (0.54-2.04)	0.14 (0.09-0.20)
Eastern:Male	0.61 (0.53-0.70)	0.69 (0.56-0.85)	0.36 (0.30-0.44)
Southern:Male	0.61 (0.55-0.66)	0.76 (0.65-0.90)	0.15 (0.11-0.20)
Sub-region:Year <sup>2</sup>			
Western and Central:Year	0.99 (0.95-1.03)	0.99 (0.94-1.04)	0.99 (0.96-1.02)
Eastern:Year	1.07 (1.05-1.09)	1.01 (0.99-1.04)	0.97 (0.94-1.01)
Southern:Year	1.02 (1.00-1.04)	1.02 (0.99-1.05)	0.96 (0.92-0.99)
Population			
ANC attendees	Ref	Ref	Ref
FP attendees	0.95 (0.63-1.45)	0.90 (0.50-1.64)	0.54 (0.32-0.90)
GYN attendees	1.03 (0.57-1.88)	0.87 (0.42-1.82)	1.34 (0.80-2.25)
PHC/OPD attendees	0.81 (0.57-1.14)	1.49 (0.92-2.39)	0.94 (0.61-1.43)
Students	1.06 (0.69-1.63)	1.14 (0.56-2.31)	1.23 (0.76-1.99)
Community members	0.97 (0.66-1.44)	1.10 (0.65-1.87)	0.96 (0.50-1.86)
HIV/STI prevention trial participants	0.89 (0.61-1.28)	1.20 (0.72-1.99)	1.00 (0.62-1.63)
Population-representative survey participants	0.90 (0.58-1.42)	1.19 (0.64-2.20)	1.32 (0.71-2.44)
Age group			
All adults (12+ years)	Ref	Ref	Ref
Younger adults (12 - 25 years)	1.14 (0.85-1.52)	1.12 (0.75-1.68)	0.55 (0.35-0.88)
HIV status			
Non-stratified	Ref	Ref	Ref
HIV negative	1.42 (1.06-1.90)	1.06 (0.71-1.59)	0.79 (0.56-1.14)
Diagnostic test			
NAAT	Ref	Ref	Ref
Culture	-	1.60 (1.00-2.54)	1.36 (0.89-2.09)
DFA	0.70 (0.32-1.51)	-	-
ELISA	2.26 (0.86-5.98)	-	-
Rapid antigen test	2.94 (1.76-4.92)	0.52 (0.06-4.61)	1.03 (0.56-1.90)
Wet mount	-	-	1.61 (1.14-2.29)
Model variance			
$ au^2$ fixed	0.51	0.16	0.45
$ au^2$ random	0.34	0.60	0.60
Number groups			
Number studies	139	140	162
Number observations	202	202	207

457 Generalised linear mixed-effects models on the risk of chlamydia, gonorrhoea, and trichomoniasis in sub-Saharan 458 Africa, using all study observations adjusted for diagnostic test performance.

459 <sup>1</sup>Reference sex is female. <sup>2</sup>Midpoint year between start and end of data collection period; centred at 2012.

460 aPR: adjusted prevalence ratio, 95% CI: 95% confidence interval, ANC: antenatal care, DFA: direct fluorescent

461 antibody, FP: family planning clinic, GYN: gynaecology clinic, NAAT: nucleic acid amplification test, PHC/OPD: primary

462 health care or outpatient department, Ref: Reference group,  $\tau^2$ : variance.



464





468 Figure 2: Sexually transmitted infection prevalence per sub-region in sub-Saharan Africa. Estimates of chlamydia, 469 gonorrhoea, and trichomoniasis prevalence by sex and sub-region. Sub-regional estimates generated using log-470 binomial generalised linear mixed-effects models for each infection. Sub-Saharan African estimates represent sex-471 matched population-weighted means. Panel A: Prevalence estimates in 2020. Bars and error lines depict mean 472 prevalence estimates with 95% confidence intervals. Panel B: Prevalence estimates between 2000 and 2024. Lines 473 and shaded areas depict mean prevalence estimates (solid line: females, dashed line: males) with 95% confidence

- intervals. Points and error lines represent study prevalence observations (solid point: female, open point: male) with
- 95% confidence intervals, colour coded according to diagnostic test category. Y-axes truncated. DFA: Direct
- 474 475 476 fluorescent antibody, EA: Eastern Africa, NAAT: nucleic acid amplification test, SA: Southern Africa, SSA: Sub-Saharan 477 Africa, WCA: Western and Central Africa.



perpetuity. It is made available under a CC-BY 4.0 International license .

## 480 Figure 3: Sexually transmitted infection male-to-female prevalence ratio estimates in sub-Saharan Africa. Study

481 observations and aggregate estimates of male-to-female prevalence ratios for (A) chlamydia, (B) gonorrhoea and (C)
 482 trichomoniasis. Ratios estimated using log-binomial generalised linear mixed-effects models per infection. Models for

trichomoniasis. Ratios estimated using log-binomial generalised linear mixed-effects models per infection. Models for
 within-study ratios used study observations among both sexes and between-study ratios used all study observations.

484 All models included sex as a fixed effect and study-level random intercepts. Pooled ratio models did not adjust for

485 additional covariates. Adjusted ratio models included fixed effects for region, year, age-group, HIV-status, diagnostic

486 test, and population group (between-study only). Points and error lines depict ratios and 95% confidence intervals for

487 studies with observations among both sexes. Diamonds depict population-weighted mean ratios and 95% confidence

488 intervals for sub-Saharan Africa, with adjusted ratios reported for 2020. Blue dotted lines and x-axis labels represent

489 WHO global male-to-female prevalence ratios.<sup>5,8</sup> Green dotted lines and x-axis labels represent the Global Burden of 490 Disease study male-to-female prevalence ratios.<sup>10</sup> X-axes are truncated. EA: Eastern Africa, SA: Southern Africa, WCA:

491 Western and Central Africa, n: number of observations,  $\tau^2$ : variance for study random intercept.